Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Niedelman’s successors

This article was originally published in The Tan Sheet

Executive Summary

FDA's Office of Regulatory Affairs will have two deputy associate commissioners for regulatory affairs following the departure Steven Niedelman, the agency announces June 22. Niedelman recently said he will leave ORA at the end of June to join Quintiles Consulting as executive vice president (1"The Tan Sheet", June 19, In Brief). Diana Kolaitis will serve as a deputy ACRA, taking the lead responsibility for the operational aspects of ORA's work, including the achievement of inspections and lab work. The second deputy post will be filled by David Horowitz, who will lead strategic operations by setting priorities, developing policies, and finding new methods with which to fill ORA's mission...

You may also be interested in...

Niedelman retires

Deputy Associate Commissioner for Regulatory Operations Steven Niedelman will retire from the agency at the end of the month, according to a June 15 announcement. He will join Quintiles Consulting as an executive vice president, FDA states...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts